Clinical Trial

Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)

Enrolling by Invitation Phase 2/3
View on ClinicalTrials.gov →
Summary
To evaluate the long-term safety and tolerability of sibeprenlimab in subjects with IgAN
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2022-02-18; most recent amendment 2026-04-29.
Status change: Active, Not Recruiting → Enrolling by Invitation 2023-03-08
Status change: Not Yet Recruiting → Active, Not Recruiting 2023-01-26
Trial Details
NCT Number NCT05248659
Lead Sponsor Otsuka Pharmaceutical Development & Commercialization, Inc.
Conditions Immunoglobulin A Nephropathy
Enrollment 600 participants
Start Date 2022-04-05
Primary Completion 2028-12-28 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-05